LBA44
Pembrolizumab vs Ipilimumab in Advanced Melanoma: 10-Year Follow-Up of the Phase 3 KEYNOTE-006 Study

LBA46
Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab